Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - Results from a randomized trial programme

P. Malfertheiner, J. Dent, L. Zeijlon, P. Sipponen, S. J O Veldhuyzen Van Zanten, C. F. Burman, T. Lind, M. Wrangstadh, E. BayerdÖrffer, J. Lonovics

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: Helicobacter pylori infection has been proposed as a protective factor against the development of gastro-oesophageal reflux disease. Aim: To study heartburn and endoscopic findings before and after H. pylori eradication therapy in patients with peptic ulcer disease. Methods: In a multicentre trial programme, patients (n = 1497) were randomized to the omeprazole triple therapy group or to the control group, and were followed for 1-6 months after treatment. Patients in whom the infection was eradicated were compared with those in whom infection persisted. The severity of heartburn was measured at baseline and at each return visit. Endoscopy was performed 6 months after therapy in two of the five studies. Results: In patients with duodenal ulcer, there was a significantly lower prevalence of heartburn after successful eradication of H. pylori relative to that after failed eradication (estimated odds ratio, 0.48). The reduction in the prevalence of heartburn in patients with gastric ulcer was independent of the posttreatment H. pylori status. In studies in which ulcer relapse was included in the model, this factor emerged as a significant factor for heartburn. The observed incidence of oesophagitis at the last visit was not influenced by H. pylori status. Conclusions: Eradication of H. pylori in patients with peptic ulcer disease was associated with a reduced prevalence of heartburn. Prevention of ulcer relapse could be the true cause of this reduction.

Original languageEnglish
Pages (from-to)1431-1442
Number of pages12
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number8
DOIs
Publication statusPublished - Aug 2002

Fingerprint

Duodenal Diseases
Heartburn
Stomach Ulcer
Duodenal Ulcer
Helicobacter pylori
Peptic Ulcer
Ulcer
Esophageal Diseases
Omeprazole
Esophagitis
Helicobacter Infections
Group Psychotherapy
Gastroesophageal Reflux
Secondary Prevention
Infection
Endoscopy
Multicenter Studies
Therapeutics
Odds Ratio
Recurrence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - Results from a randomized trial programme. / Malfertheiner, P.; Dent, J.; Zeijlon, L.; Sipponen, P.; Veldhuyzen Van Zanten, S. J O; Burman, C. F.; Lind, T.; Wrangstadh, M.; BayerdÖrffer, E.; Lonovics, J.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 8, 08.2002, p. 1431-1442.

Research output: Contribution to journalArticle

Malfertheiner, P, Dent, J, Zeijlon, L, Sipponen, P, Veldhuyzen Van Zanten, SJO, Burman, CF, Lind, T, Wrangstadh, M, BayerdÖrffer, E & Lonovics, J 2002, 'Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - Results from a randomized trial programme', Alimentary Pharmacology and Therapeutics, vol. 16, no. 8, pp. 1431-1442. https://doi.org/10.1046/j.1365-2036.2002.01285.x
Malfertheiner, P. ; Dent, J. ; Zeijlon, L. ; Sipponen, P. ; Veldhuyzen Van Zanten, S. J O ; Burman, C. F. ; Lind, T. ; Wrangstadh, M. ; BayerdÖrffer, E. ; Lonovics, J. / Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - Results from a randomized trial programme. In: Alimentary Pharmacology and Therapeutics. 2002 ; Vol. 16, No. 8. pp. 1431-1442.
@article{e01a0888cf2447558820296ee44d9441,
title = "Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - Results from a randomized trial programme",
abstract = "Background: Helicobacter pylori infection has been proposed as a protective factor against the development of gastro-oesophageal reflux disease. Aim: To study heartburn and endoscopic findings before and after H. pylori eradication therapy in patients with peptic ulcer disease. Methods: In a multicentre trial programme, patients (n = 1497) were randomized to the omeprazole triple therapy group or to the control group, and were followed for 1-6 months after treatment. Patients in whom the infection was eradicated were compared with those in whom infection persisted. The severity of heartburn was measured at baseline and at each return visit. Endoscopy was performed 6 months after therapy in two of the five studies. Results: In patients with duodenal ulcer, there was a significantly lower prevalence of heartburn after successful eradication of H. pylori relative to that after failed eradication (estimated odds ratio, 0.48). The reduction in the prevalence of heartburn in patients with gastric ulcer was independent of the posttreatment H. pylori status. In studies in which ulcer relapse was included in the model, this factor emerged as a significant factor for heartburn. The observed incidence of oesophagitis at the last visit was not influenced by H. pylori status. Conclusions: Eradication of H. pylori in patients with peptic ulcer disease was associated with a reduced prevalence of heartburn. Prevention of ulcer relapse could be the true cause of this reduction.",
author = "P. Malfertheiner and J. Dent and L. Zeijlon and P. Sipponen and {Veldhuyzen Van Zanten}, {S. J O} and Burman, {C. F.} and T. Lind and M. Wrangstadh and E. Bayerd{\"O}rffer and J. Lonovics",
year = "2002",
month = "8",
doi = "10.1046/j.1365-2036.2002.01285.x",
language = "English",
volume = "16",
pages = "1431--1442",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - Results from a randomized trial programme

AU - Malfertheiner, P.

AU - Dent, J.

AU - Zeijlon, L.

AU - Sipponen, P.

AU - Veldhuyzen Van Zanten, S. J O

AU - Burman, C. F.

AU - Lind, T.

AU - Wrangstadh, M.

AU - BayerdÖrffer, E.

AU - Lonovics, J.

PY - 2002/8

Y1 - 2002/8

N2 - Background: Helicobacter pylori infection has been proposed as a protective factor against the development of gastro-oesophageal reflux disease. Aim: To study heartburn and endoscopic findings before and after H. pylori eradication therapy in patients with peptic ulcer disease. Methods: In a multicentre trial programme, patients (n = 1497) were randomized to the omeprazole triple therapy group or to the control group, and were followed for 1-6 months after treatment. Patients in whom the infection was eradicated were compared with those in whom infection persisted. The severity of heartburn was measured at baseline and at each return visit. Endoscopy was performed 6 months after therapy in two of the five studies. Results: In patients with duodenal ulcer, there was a significantly lower prevalence of heartburn after successful eradication of H. pylori relative to that after failed eradication (estimated odds ratio, 0.48). The reduction in the prevalence of heartburn in patients with gastric ulcer was independent of the posttreatment H. pylori status. In studies in which ulcer relapse was included in the model, this factor emerged as a significant factor for heartburn. The observed incidence of oesophagitis at the last visit was not influenced by H. pylori status. Conclusions: Eradication of H. pylori in patients with peptic ulcer disease was associated with a reduced prevalence of heartburn. Prevention of ulcer relapse could be the true cause of this reduction.

AB - Background: Helicobacter pylori infection has been proposed as a protective factor against the development of gastro-oesophageal reflux disease. Aim: To study heartburn and endoscopic findings before and after H. pylori eradication therapy in patients with peptic ulcer disease. Methods: In a multicentre trial programme, patients (n = 1497) were randomized to the omeprazole triple therapy group or to the control group, and were followed for 1-6 months after treatment. Patients in whom the infection was eradicated were compared with those in whom infection persisted. The severity of heartburn was measured at baseline and at each return visit. Endoscopy was performed 6 months after therapy in two of the five studies. Results: In patients with duodenal ulcer, there was a significantly lower prevalence of heartburn after successful eradication of H. pylori relative to that after failed eradication (estimated odds ratio, 0.48). The reduction in the prevalence of heartburn in patients with gastric ulcer was independent of the posttreatment H. pylori status. In studies in which ulcer relapse was included in the model, this factor emerged as a significant factor for heartburn. The observed incidence of oesophagitis at the last visit was not influenced by H. pylori status. Conclusions: Eradication of H. pylori in patients with peptic ulcer disease was associated with a reduced prevalence of heartburn. Prevention of ulcer relapse could be the true cause of this reduction.

UR - http://www.scopus.com/inward/record.url?scp=0036668703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036668703&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01285.x

DO - 10.1046/j.1365-2036.2002.01285.x

M3 - Article

VL - 16

SP - 1431

EP - 1442

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -